Upsher-Smith gets FDA OK on Namenda generic

MAPLE GROVE, Minn. — The Food and Drug Administration has approved Upsher-Smith Laboratories’ generic of Namenda. The company’s memantine hydrochloride tablets, available in 5- and 10-mg dosage strengths, are meant to treat dementia associated with Alzheimer’s disease.

“Approximately 5.3 million Americans suffer from Alzheimer's disease,” Upsher-Smith President Rusty Field said. “With the FDA approval of Upsher-Smith's generic Memantine Hydrochloride Tablets, it is our hope to increase access to a cost-effective alternative to Namenda for those patients experiencing moderate to severe dementia of the Alzheimer's type.”